Kamada Is Bringing Reduction To These With Uncommon And Critical Circumstances – Kamada (NASDAQ:KMDA)

Amir London, CEO of Kamada Prescription drugs KMDA, was not too long ago a visitor on Benzinga’s All-Entry.

Kamada is a worldwide biopharmaceutical firm with a portfolio of property indicated for uncommon and critical situations. The corporate experiences it’s a chief within the specialty plasma-derived area, targeted on ailments with restricted remedy options.

Mr. London was on this system to debate thrilling developments within the firm’s growth pipeline in addition to Mr. London’s technique for M&A.

Watch the complete interview right here:

Featured photograph by Hal Gatewood on Unsplash.

This submit accommodates sponsored content material. This content material is for informational functions solely and never supposed to be investing recommendation.